Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum

Vaccine

Volumn 24, Issue 14, 2006, Pages 2460-2468

  Poot, J ^a   Spreeuwenberg, K ^a   Sanderson, S J ^b   Schijns, V E C J ^a   Mottram, J C ^c   Coombs, G H ^d   Vermeulen, A N ^a  

^a INTERVET INTERNATIONAL BV   (Netherlands)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Canine; Cysteine peptidases; IL 12; Leishmania infantum; Vaccination

Indexed keywords

IMMUNOLOGICAL ADJUVANT; PROTOZOAL VACCINE; QUIL A; RECOMBINANT CANINE INTERLEUKIN 12; RECOMBINANT CYSTEINE PEPTIDASE A; RECOMBINANT CYSTEINE PEPTIDASE B; RECOMBINANT ENZYME; RECOMBINANT INTERLEUKIN 12; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL INFECTION; HOST PARASITE INTERACTION; HUMORAL IMMUNITY; INFECTION PREVENTION; LEISHMANIA INFANTUM; LEISHMANIASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN CONFORMATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYSTEINE ENDOPEPTIDASES; DOG DISEASES; DOGS; INTERLEUKIN-12; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; PROTOZOAN VACCINES; VACCINATION; VACCINES, DNA;

EID: 33344478719     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.12.039     Document Type: Article

References (49)

1. L. Baldi, V. Mizzoni, and A. Guarino Canine leishmaniasis in Campania: new and old foci Parassitologia 46 1-2 2004 217 220
2. G. Capelli, R. Baldelli, E. Ferroglio, C. Genchi, L. Gradoni, and M. Gramiccia Monitoring of canine leishmaniasis in northern Italy: an update from a scientific network Parassitologia 46 1-2 2004 193 197
3. L. Cardoso, F. Neto, J.C. Sousa, M. Rodrigues, and M. Cabral Use of a leishmanin skin test in the detection of canine Leishmania-specific cellular immunity Vet Parasitol 79 3 1998 213 220
4. R. Fisa, M. Gallego, S. Castillejo, M.J. Aisa, T. Serra, and C. Riera Epidemiology of canine leishmaniosis in Catalonia (Spain) the example of the Priorat focus Vet Parasitol 83 2 1999 87 97
5. P.J. Ginel, R. Lucena, R. Lopez, and J.M. Molleda Use of allopurinol for maintenance of remission in dogs with leishmaniasis J Small Anim Pract 39 6 1998 271 274
6. G. Baneth, and S.E. Shaw Chemotherapy of canine leishmaniosis Vet Parasitol 106 4 2002 315 324
7. C. Dye The logic of visceral leishmaniasis control Am J Trop Med Hyg 55 2 1996 125 130
8. R.B. Tesh Control of zoonotic visceral leishmaniasis: is it time to change strategies? Am J Trop Med Hyg 52 3 1995 287 292
9. J.H. McKerrow Parasite proteases Exp Parasitol 68 1 1989 111 115
10. J.C. Mottram, G.H. Coombs, and J. Alexander Cysteine peptidases as virulence factors of Leishmania Curr Opin Microbiol 7 4 2004 375 381
11. J. Alexander, G.H. Coombs, and J.C. Mottram Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response J Immunol 161 12 1998 6794 6801
12. K.G. Pollock, K.S. McNeil, J.C. Mottram, R.E. Lyons, J.M. Brewer, and P. Scott The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses J Immunol 170 4 2003 1746 1753
13. T. Aebischer, M. Wolfram, S.I. Patzer, T. Ilg, M. Wiese, and P. Overath Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants Infect Immun 68 3 2000 1328 1336
14. S. Rafati, A.A. Baba, M. Bakhshayesh, and M. Vafa Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase Clin Exp Immunol 120 1 2000 134 138
15. S. Rafati, A.H. Salmanian, T. Taheri, M. Vafa, and N. Fasel A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major Vaccine 19 25-26 2001 3369 3375
16. G.E. Hancock, K.M. Heers, and J.D. Smith QS-21 synergizes with recombinant interleukin-12 to create a potent adjuvant formulation for the fusion protein of respiratory syncytial virus Viral Immunol 13 4 2000 503 509
17. S. Silla, F. Fallarino, T. Boon, and C. Uyttenhove Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL Eur Cytokine Netw 10 2 1999 181 190
18. R.L. Berens, R. Brun, and S.M. Krassner A simple monophasic medium for axenic culture of hemoflagellates J Parasitol 62 3 1976 360 365
19. E.L. McMonagle, S. Taylor, H. van Zuilekom, L. Sanders, N. Scholtes, and L.J. Keanie Production of biologically active equine interleukin 12 through expression of p35, p40 and single chain IL-12 in mammalian and baculovirus expression systems Equine Vet J 33 7 2001 693 698
20. O.H. Lowry, N. Rosebrough, A. Farr, and R. Randall Protein measurement with the Folin phenol reagent J Biol Chem 193 1 1951 265 275
21. J. Poot, M.E. Rogers, P.A. Bates, and A. Vermeulen Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs Vet Parasitol 130 1-2 2005 41 53
22. A. Rhalem, H. Sahibi, N. Guessous-Idrissi, S. Lasri, A. Natami, and M. Riyad Immune response against Leishmania antigens in dogs naturally and experimentally infected with Leishmania infantum Vet Parasitol 81 3 1999 173 184
23. A. Martinez-Moreno, T. Moreno, F.J. Martinez-Moreno, I. Acosta, and S. Hernandez Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis Vet Immunol Immunopathol 48 3-4 1995 209 220
24. M. Cabral, J.E. O'Grady, S. Gomes, J.C. Sousa, H. Thompson, and J. Alexander The immunology of canine leishmaniosis: strong evidence for a developing disease spectrum from asymptomatic dogs Vet Parasitol 76 3 1998 173 180
25. L. Solano-Gallego, J. Llull, G. Ramos, C. Riera, M. Arboix, and J. Alberola The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection Vet Parasitol 90 1-2 2000 37 45
26. M. Mohebali, A. Khamesipour, I. Mobedi, Z. Zarei, and R. Hashemi-Fesharki Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran Vaccine 22 29-30 2004 4097 4100
27. G.P. Borja-Cabrera, N.N. Correia Pontes, V.O. da Silva, de Souza Paraguai, W.R. Santos, and E.M. Gomes Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN) Vaccine 20 27-28 2002 3277 3284
28. V.O. da Silva, G.P. Borja-Cabrera, N.N. Correia Pontes, E.P. de Souza, K.G. Luz, and M. Palatnik A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN) Vaccine 19 9-10 2000 1082 1092
29. J.L. Lemesre, P. Holzmuller, M. Cavaleyra, R.B. Goncalves, G. Hottin, and G. Papierok Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes Vaccine 23 22 2005 2825 2840
30. I. Molano, M.G. Alonso, C. Miron, E. Redondo, J.M. Requena, and M. Soto A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum Vet Immunol Immunopathol 92 1-2 2003 1 13
31. Moreno J, Nieto J, Masina S, et al. Immunization with H1 and HASPB1 leishmania proteins protect dogs against experimental canine leishmaniasis. (Abstract) Abstract Book Third World Congress on Leishmaniosis 2005; (10-15 April 2005. Palermo, Italy) p. 178.
32. L. Gradoni, V. Foglia Manzillo, A. Pagano, D. Piantedosi, R. De Luna, and M. Gramiccia Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals Vaccine 23 45 2005 5245 5251
33. M.J. Ramiro, J.J. Zarate, T. Hanke, D. Rodriguez, J.R. Rodriguez, and M. Esteban Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK Vaccine 21 19-20 2003 2474 2484
34. R.M. Gonzalo, G. del Real, J.R. Rodriguez, D. Rodriguez, R. Heljasvaara, and P. Lucas A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis Vaccine 20 7-8 2002 1226 1231
35. R.M. Gonzalo, J.R. Rodriguez, D. Rodriguez, G. Gonzalez-Aseguinolaza, V. Larraga, and M. Esteban Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36 Microbes Infect 3 9 2001 701 711
36. A. Campos-Neto, R. Porrozzi, K. Greeson, R.N. Coler, J.R. Webb, and Y.A. Seiky Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease Infect Immun 69 6 2001 4103 4108
37. Y.A. Skeiky, R.N. Coler, M. Brannon, E. Stromberg, K. Greeson, and R.T. Crane Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant Vaccine 20 27-28 2002 3292 3303
38. S. Stager, D.F. Smith, and P.M. Kaye Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis J Immunol 165 12 2000 7064 7071
39. S. Rafati, A. Nakhaee, T. Taheri, Y. Taslimi, H. Darabi, and D. Eravani Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum Vaccine 23 28 2005 3716 3725
40. J. Martinez, O. Campetella, A.C. Frasch, and J.J. Cazzulo The reactivity of sera from chagasic patients against different fragments of cruzipain, the major cysteine proteinase from Trypanosoma cruzi, suggests the presence of defined antigenic and catalytic domains Immunol Lett 35 2 1993 191 196
41. A. Nakhaee, T. Taheri, M. Taghikhani, M. Mohebali, A.H. Salmanian, and N. Fasel Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population Vet Parasitol 119 2-3 2004 107 123
42. G. Gonzalez, D. Sunnemark, A. Orn, and K.O. Gronvik Detection of cruzipain, the major cysteine proteinase from Trypanosoma cruzi and its C-terminal extension in biological fluids during experimental infection in mice Scand J Immunol 44 2 1996 122 128
43. A. Sjolander, T.M. Baldwin, J.M. Curtis, K.L. Bengtsson, and E. Handman Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection Vaccine 16 20 1998 2077 2084
44. E. Handman, L.L. Button, and R.W. McMaster Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice Exp Parasitol 70 4 1990 427 435
45. L.C. Afonso, T.M. Scharton, L.Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott The adjuvant effect of interleukin-12 in a vaccine against Leishmania major Science 263 5144 1994 235 237
46. S.L. Reiner, and R.M. Locksley The regulation of immunity to Leishmania major Annu Rev Immunol 13 1995 151 177
47. F.P. Heinzel Interleukin 12 and the regulation of CD4+ T-cell subset responses during murine Leishmaniasis Parasitol Today 10 5 1994 190 192
48. A.H. Noormohammadi, H. Hochrein, J.M. Curtis, T.M. Baldwin, and E. Handman Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen Vaccine 19 28-29 2001 4043 4052
49. G.M. Santos-Gomes, R. Rosa, C. Leandro, S. Cortes, P. Romao, and H. Silveira Cytokine expression during the outcome of canine experimental infection by Leishmania infantum Vet Immunol Immunopathol 88 1-2 2002 21 30